NCT05676034Phase 2Active not recruiting

AMX0035 in Adult Patients With Wolfram Syndrome

Study sponsor: Amylyx Pharmaceuticals Inc. · AMLX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-07-23Actual
Enrollment · participants12Actual
Source updated2026-04-14Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT) Measure: To assess the safety and tolerability of AMX0035 administered orally for up to 144 weeks in adult participants with Wolfram syndrome. After: Measure: To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT) Measure: To assess the safety and tolerability of AMX0035 administered orally for up to 208 weeks in adult participants with Wolfram syndrome.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview